Navigation Links
Novel Drug Eases Osteoarthritis Knee Pain
Date:9/29/2010

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, Sept. 29 (HealthDay News) -- A new painkilling drug called tanezumab appears effective in relieving knee pain from osteoarthritis, researchers are reporting.

But the U.S. Food and Drug Administration has halted a phase 3 trial of the drug after 16 patients developed worsened arthritis and underwent joint replacements.

Lead researcher Dr. Nancy E. Lane, director of the Aging Center, Medicine and Rheumatology at the University of California, Davis, said those patients who ended up needing a knee replacement most likely overworked their damaged joint because they were feeling no pain.

"They probably accelerated the degeneration of the joint," she said. "Sometimes, pain is good in protecting you."

The study findings were published in the Sept. 30 issue of the New England Journal of Medicine.

Tanezumab is made by Pfizer Inc., which funded the trial. Whether the osteoarthritis portion of the phase 3 trial will resume is up in the air. Pfizer spokesman Mackay Jimeson said the company is still in discussions with the FDA, and no decisions about the drug's future have been made.

For the study, Lane's team randomly assigned 450 patients with osteoarthritis of the knee to receive either tanezumab or a placebo. Those taking tanezumab had their pain reduced anywhere from 45 percent to 62 percent, compared with those given a placebo, who saw their pain reduced 22 percent, on average.

Lane said tanezumab, which is given by injection, should probably not be used frequently. The effect of the drug can last at least eight weeks, she added, but no studies have been done yet on its long-term effects.

The drug works in a unique way by blocking nerve growth factor (NGF), which is essential for normal development of the nervous system, but is also released when there is inflammation. NGF stimulates nerve cells and triggers pain, Lane explained.

"By inhibiting NGF, we really get a dramatic reduction in pain in patients who have pretty severe osteoarthritis," she said. "It doesn't do anything to the disease, it doesn't hurt your stomach, it doesn't change how you think or make you groggy. This is a real game-changer."

The phase 3 trial is also testing the drug in patients with cancer pain, interstitial cystitis, chronic low back pain, and diabetic nerve pain.

Dr. Elaine Tozman, associate professor in the division of rheumatology and immunology at the University of Miami Miller School of Medicine, said she doesn't think this new painkiller would add much to the treatment of osteoarthritis.

"This is really a drug which is for a symptom of osteoarthritis, it's really for pain," she said. "As rheumatologists, most of us are looking for a drug that works on the underlying disease."

Tozman noted that patients with severe osteoarthritis of the knee usually go on to have a joint replacement.

Some 27 million adults in the United States have osteoarthritis, with the knee being the most affected joint, according to the U.S. Centers for Disease Control and Prevention.

The number of people with osteoarthritis of the knee is expected to rise as baby boomers age and as obesity among Americans increases, Lane said.

More information

For more on osteoarthritis, visit the U.S. National Library of Medicine.

SOURCES: Nancy E. Lane, M.D., director and distinguished professor, Aging Center, Medicine and Rheumatology, University of California, Davis, Sacramento; Elaine Tozman, M.D., associate professor, division of rheumatology and immunology, University of Miami Miller School of Medicine; Mackay Jimeson, spokesman, Pfizer Inc., New York City; Sept. 29, 2010, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... SANTA CLARA, CA (PRWEB) , ... July 24, 2017 , ... ... government and financial organizations, today announced it has partnered with WALLIX to ... NIST Special Publication 800-171 . , There are a number of ways to address ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they ... would a pharmacist using that same scale to dispense medication. The first example is ... These illustrations show why it is important to have the right balance for the ...
(Date:7/24/2017)... ... 24, 2017 , ... A Southern California-based author has released a new book ... she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle V. Madsen, highlights ... risen above. , In “Memories,” readers get a firsthand look at what Michelle has ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... how to change manufacturers future. , The agency is hammering out a game ... one of the farthest-ranging laws ever to affect FDA-regulated firms. The new law:, ...
(Date:7/24/2017)... ... 24, 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir ... of published author, Ed Clark. Ed Clark is a church music director and ... a minister of music and worship leader for over fifty years. He has ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/5/2017)... 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... received approval from the Israel Securities Authority to dual-list its ... common stock will commence trading on the TASE on July ... market capitalization of the Company, it is expected that Oramed ...
(Date:6/30/2017)... -- AVACEN Medical (AVACEN) announced the publication of new research in the ... its AVACEN Treatment Method to significantly reduce the widespread ... ... ... approximately 200 to 400 million people worldwide according to The National ...
Breaking Medicine Technology: